Silence Therapeutics logo

SLN - Silence Therapeutics Share Price

438p -2.0  -0.5%

Last Trade - 22/11/19

Sector
Healthcare
Size
Small Cap
Market Cap £344.7m
Enterprise Value £328.2m
Revenue £n/a
Position in Universe 652nd / 1847
Bullish
Bearish
Unlock SLN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SLN Revenue Unlock SLN Revenue

Net Income

SLN Net Income Unlock SLN Revenue

Normalised EPS

SLN Normalised EPS Unlock SLN Revenue

PE Ratio Range

SLN PE Ratio Range Unlock SLN Revenue

Dividend Yield Range

SLN Dividend Yield Range Unlock SLN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SLN EPS Forecasts Unlock SLN Revenue
Profile Summary

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated November 18, 1994
Public Since January 5, 2010
No. of Shareholders: n/a
No. of Employees: 45
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (Full)
Shares in Issue 78,338,279
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SLN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SLN
Upcoming Events for SLN
Similar to SLN
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.